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Abstract 
Four mononuclear copper(I1) complexes have been prepared by allowing copper(I1) aspirinate to react with 
benzimidazole, 2-methylbenzimidazole, metronidazole or 2-methyl-5nitrobenzimidazoIe Iigands. Elemental analyses, 
UV-Vis, IR, EPR and magnet moment data are consistent with mononuclear square planar complexes that 
contain two aspirinate Iigands and two N-containing ligands to give a CuOrN, chromophore. The benzimidazole, 
2-methylbenzimidazole and metronidazole complexes catalyze the oxidation of catechol to o-quinone. This reaction 
was monitored spectrophotometrically by following the increase in intensity of the o-quinone band at 390 nm 
with time. Enzyme-mimetic activity of these copper complexes was determined and expressed as micromoles of 
substrate per mg catalyst per min. The activities were found to be 0.314 for the benzimidazole complex, 0.0998 
for the 2-methylbenzimidazole complex, and 0.129 for the metronidazole complex. In the case of the 2-methyl- 
5nitrobenzimidazoIe complex the initial formation of o-quinone is very rapid; however, after 2-3 min the catalyst 
is poisoned and the concentration of o-quinone drops slightly and remains constant. 
Introduction 
Salicylic acid and its derivatives including aspirin 
(acetylsalicyclic acid) have been used for many years 
as antiinflammatory, antipyretic and analgesic drugs. 
Copper(I1) complexes of aspirin and other salicylic acid 
derivatives have been found to be more potent and 
desirable drugs than their constituent ligands [l, 21. In 
addition, animal studies have shown that copper com- 
plexes exhibit a variety of pharmacological effects such 
as antiinflammatory, analgesic, antiulcer, antidiabetic, 
anticancer, anticonvulsant and radiation recovery ac- 
tivities [l-6]. X-ray analysis of copper(I1) aspirinate 
has shown that it contains binuclear units with bridging 
carboxylate ligands [7], similar to other Cu(I1) car- 
boxylates including copper(I1) acetate [8, 91. Reaction 
of copper(I1) aspirinate with pyridine produces the 
more soluble mononuclear adduct bis(aspirinato)bis- 
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(pyridine)copper(II) [lo] which exhibits enhanced an- 
titumor activity [ll] and has been shown by X-ray 
analysis to contain the CuN,O, chromophore in a tram 
square-planar arrangement [lo]. Fyridine adducts and 
other mononuclear adducts of copper(I1) aspirinate 
that contain picoline or imidazole derivatives have 
recently been reported to have superoxide dismutase- 
mimetic activity [12]. 
As a continuation of our work on the interaction of 
copper(I1) carboxylates with imidazoles [13, 141 as 
models for copper proteins that contain both the im- 
idazole and carboxylate functionalities in the side chain 
[15], one of us recently reported the characterization 
of mononuclear tetrakis-adducts of copper(I1) aspirinate 
with imidazole or N-methylimidazole and the bis-adduct 
with 1,2-dimethylimidazole [13]. Since benzimidazoles 
and nitroimidazoles are used as chemotherapeutic 
agents, particularly nitroimidazoles, in the treatment 
of bacterial infections and as radiosensitizer agents [16, 
171, we have extended our studies to include interactions 
of these and other imidazole derivatives with copper(I1) 
aspirinate and other copper(I1) carboxylates. 
Interest in developing small molecular weight cop- 
per(II)compl as models for copper oxidase enzymes 
have led to the synthesis of many dinuclear [G-21] 
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and mononuclear [22, 231 copper(I1) complexes; the 
idea being that these complexes might mimic the be- 
havior of various metalloproteins, such as the copper- 
containing protein tyrosinase. One reaction catalyzed 
by this metalloenzyme is the oxidation of catechols to 
their respective o-quinones [24]. It therefore is of interest 
to investigate the potential of metalloenzyme model 
complexes to catalyze the oxidation of catechols to 
quinones. This article reports the synthesis, spectro- 
scopic characterization and catecholase-mimetic activity 
of four mononuclear copper(I1) aspirinate benzimi- 
dazole or metronidazole bis-adducts. 
Experimental 
All chemicals were of high purity grade (Aldrich 
Chemical Co.) and used without further purification. 
All solvents were anhydrous. Tetrakis-p-aspirinatodi- 
copper [WaspM was prepared according to a 
published procedure [l]. 
Physical measurements 
Magnetic moments were determined at 298 K by the 
Evans method [25] with an NMC/NMR-1280 (200 MHz) 
spectrometer (Bruker). Methanol was used as the solvent 
and benzene as the reference. The effective magnetic 
moment is related to the reference shift, Au (Hz), at 
any temperature by the expression: ~~R=0.0618(AvT/ 
VM)1’2, where v is the NMR frequency in MHz and 
M is the molariiy of the paramagnetic substance. 
Electronic spectra of methanol solutions were ob- 
tained with a Hewlett Packard 8452A diode array 
spectrophotometer. Nujol mulls sealed between poly- 
ethylene sheets were used to obtain IR spectra in the 
4000-450 cm-l region with a FTS-7 Bio-Rad SPC 3200 
Fourier transform IR spectrometer. X-band EPR spec- 
tra of polycrystalline material and of methanol/toluene 
solutions were obtained at room temperature and 77 
K with and ESPIT-330 Vol.501 spectrometer. Di- 
phenylpicrylhydrazide (DPPH, g = 2.0036) was used as 
the calibrating field marker. 
The catecholase-mimetic activities of these complexes 
in air were followed spectrophotometrically by moni- 
toring the increase in the o-quinone absorbance at 390 
nm as a function of time. Methanol solutions of the 
copper(I1) complex (0.3 ml of a 3x 10W3 M) and 2.0 
ml of a methanol solution (1.5 X 10-l M) of catechol 
were combined in a 1 cm quartz cell at 298 K and the 
absorbance changes at 390 nm were recorded. 
Preparation of bk(aspirinato)btk(benzimidazole)2- 
copper (U Cu (asp),(bnz), 
A solution of 0.287 g (2.43 mmol) of benzimidazole 
in 100 ml of methanol was added to 0.5 g (0.593 mmol) 
of Cu,(asp),. The mixture was stirred at about 50-60 
“C for 1 h. The green solution was filtered and left in 
the hood to evaporate. The green precipitate was col- 
lected, washed with anhydrous ether, and dried in a 
desiccator over anhydrous calcium chloride. Anal. Calc. 
for C&2H26N40sCu: C, 58.40; H, 3.95; N, 8.52. Found: 
C, 58.22; H, 3.75; N, 8.39%. 
Preparation of bis(aspirinato)bk(2-methylbenzimidazole)- 
copper (2) Cu (asp),(2mbnz), 
This bluish green complexwas prepared by the method 
described for 1 except that 2-methylbenzimidazole 0.321 
g (2.43 mmol) was used in place of benzimidazole. 
Anal. Calc. for C&H30N408C~: C, 59.51; H, 4.37; N, 
8.17. Found C, 59.39; H, 4.52; N, 8.44%. 
Preparation of bis(aspirinato)bis(metronidazole)- 
copper (3), Cu (asp),(mtnd)2 
A solution of 0.416 g (2.43 mmol) metronidazole in 
100 ml of ethanol and 25 ml of methanol was added 
to 0.5 g (0.593 mmol) of Cu2(asp)4. The mixture was 
stirred and refluxed for about 4 h. The olive green 
solution was filtered while hot and left in the hood to 
evaporate. The green precipitate that formed was 
washed with anhydrous ether and dried in a desiccator 
over calcium chloride. Anal. Calc. for C&,H,,N,O,,Cu; 
C, 47.15; H, 4.19; N, 11.00. Found: C, 46.13; H, 4.22; 
N, 11.28%. 
Preparation of Bis(aspirinato)bis(2-methyl-5 
nitrobenzimidazole)copper(II) (4) Cu(asp),(2mSnbnz), 
This green complex was prepared by the method 
described for 3 except that 2-methyl-5-nitrobenzimi- 
dazole 0.430 g (2.43 mmol) was used in place of 
metronidazole.Anal. Calc. for C,,H,,N,O,,Cu: C, 52.61; 
H, 3.61; N, 10.83. Found: C, 52.51; H, 3.43; N, 10.55%. 
Elemental analyses were performed by Galbraith 
Laboratories, Knoxville, TN, USA and Desert Analytic, 
Tucson, AZ, USA. 
Results and discussion 
Magnetic and spectroscopic results 
The effective magnetic moments and electronic and 
IR spectral data are summarized in Table 1. The room- 
temperature magnetic moments for these four complexes 
are in the range 1.84-1.90 BM. These values are con- 
sistent with the presence of one unpaired electron in 
a mononuclear copper(I1) complex. 
The electronic spectra for these complexes obtained 
in methanol solution exhibit one broad absorption band 
near 700-730 nm and a weak shoulder in the 400-420 
nm region (Table 1). The broad band is assigned to 
the copper(I1) d-d transition and the shoulder to ligand- 
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TABLE 1. Magnetic moments and spectral data for Cu(I1) complexes 
Compound 
1 
2 
3 
4 
~Lcff (BM) k,(nm) (6) ~.S(COO) %(COO) %&C= 0) 
(298 K) (cm-‘) (cm-‘) (cm-l) 
1.88 695 (86) 1598 1392 1745 
1.90 706 (82) 1595 1403 1743 
1.84 730 (72) 1602 1390 1745 
1.85 714 (85) 1600 1390 1742 
‘E in units of drn3 mol-’ cm-‘. 
to-metal charge transfer. A similar shoulder also at- 
tributed to charge transfer was previously observed for 
mononuclear copper(I1) salicylate complexes [26]. The 
position of the band of the copper(I1) d-d transition 
and the magnitude of its molar absorptivity are in the 
range expected for mononuclear copper(B) carboxylate 
adducts [S, 12-141. These values are indeed comparable 
to those found for mononuclear copper(I1) aspirinate 
adducts with imidazoles or pyridines, and with those 
of other tetragonally distorted copper(I1) complexes 
that contain a CuN,O,- - -0, chromophore [12-14,261. 
The IR frequencies for the carboxyl and acetoxy 
carbonyl vibrations are given in Table 1. X-ray analysis 
of Cu,(asp), revealed two types of acetoxy carbonyl 
groups [7]. One type is weakly bonded to a copper(I1) 
atom of a neighboring copper(I1) aspirinate molecule, 
while the other is not. As a consequence, the IR spectrum 
of Cu,(asp), shows two different acetoy carbonyl 
stretching frequencies at 1758 and 1725 cm-l. The IR 
spectra for complexes l-4 show one strong acetoxy 
carbonyl band near 1745 cm-l (Table 1). The asym- 
metric v&COO) and the symmetric vs(COO) fre- 
quencies for Cu,(asp), occur at 1620 and 1415 cm-l, 
respectively, and are similar to those reported for other 
dinuclear copper(I1) carboxylates [8, 9, 271, in which 
the carboxylate acts as a ‘bridging’ bidentate ligand. 
The IR spectra for the four mononuclear complexes 
show strong V&COO) at about 1600 cm-’ with a 
shoulder at about 1625 cm-‘. The v,(COO) in these 
complexes occurs between 1390 and 1403 cm-’ (Table 
1). The positions of these carboxylate stretching vi- 
brations and the separation between them are in the 
range expected for carboxylate groups that act essentially 
as a monodentate or asymmetric bidentate ligands [lo, 
13, 14, 271. These parameters are comparable to those 
reported for mononuclear copper(I1) aspirinate com- 
plexes that contain pyridines [lo, 121 or imidazoles [12, 
131. The stretching vibrations of the NO, group in 3 
and 4 occur at 1535 and 1521 cm-l, respectively. 
The EPR parameters, g and A, for the frozen solution 
and the polycrystalline forms of the complexes studied 
are given in Table 2. A representative frozen solution 
EPR spectrum is that of 2 shown in Fig. l(A). Frozen 
solution EPR spectra of complexes l-4 exhibit resolved 
structure with g,, >gl and are consistent with a te- 
tragonally elongated structure [28]. The g, regions of 
these spectra exhibit 14N super-hyperfine structure con- 
sisting of five lines. This structure is attributed to the 
presence of two nitrogen atoms in a plane of the 
copper(I1) atom. Spectral parameters for complexes 
l-4 are comparable to those of previously reported 
complexes that essentially contain the CuN,O, chro- 
mophore in a tram or cis square-planar arrangement 
[lo, 12-14, 291, including those reported for mono- 
nuclear copper(I1) aspirinate complexes of pyridines 
or imidazoles [lo, 12, 131. These complexes contain a 
copper(I1) atom in a tram or cis arrangement of two 
ligand nitrogen atoms and one oxygen atom from each 
of the two carboxylate ligands. The second oxygen atom 
of each carboxylate ligand is weakly bonded in an axial 
arrangement. Solid-state EPR spectra of 2, 3 and 4 
are anisotropic and contain g,, and g, components with 
the g,, component exhibiting Cu hyperfine coupling. 
The solid-state EPR spectrum of 3 is shown in Fig. 
l(B) as being representative of these spectra. The solid- 
state EPR spectrum of 1 contains an asymmetric signal 
centered near 3150 G. Spectra similar to this are 
exhibited by bis-adducts of copper(I1) acetate and cop- 
per(I1) ferrocenecarboxylate with 1,2-dimethylimida- 
zole. We have determined by X-ray analysis that these 
adducts contain the CuN,O, chromophore in a ck 
square-planar arrangement [14, 301. The lack of cop- 
per(I1) hyperfme coupling in these complexes is likely 
due to dipoledipole interactions between copper atoms 
of neighboring molecules. The spectral data strongly 
suggest the presence of the CuN,O, (or CuN,O, - . . 0,) 
chromophore in a tran.s or cis square-planar arrangement 
for the bis-adducts 14. 
Catecholase-mimetic activity 
Since o-quinone shows a characteristic absorption 
band at 390 nm, the catalytic oxidation of catechol to 
o-quinone by copper(I1) complexes can be easily fol- 
lowed spectrophotometrically. The change in absor- 
bance at 390 nm versus time for the first 30 min of 
the reaction with complexes 1, 2 and 3 is depicted in 
Fig. 2 while the behavior of 4 is demonstrated in the 
insert in Fig. 2. Although o-quinone is produced in the 
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TABLE 2. EPR and kinetic data for the oxidation of catechol by Cu(I1) complexes 
Compound State g1 gll AlI, Cu A N Activity” 
(X lo4 cm-‘) ( x’io4 cm-‘) 
1 soIidb 0.314 
E 2.07 2.29 171 14 
2 solid 2.09 2.29 167 0.0998 
c 2.07 2.30 166 15 
3 solid 2.07 2.30 168 0.129 
c 2.06 2.31 166 13 
4 solid 2.07 2.29 168 
E 2.06 2.30 167 14 
“The activity is reported as moles of substrate per mg catalyst per min. bOnly a broad peak is observed with g=2.13. ‘Frozen solution. 
Fig. 1. (A) Frozen-solution EPR spectrum of 2, (B) solid-state 
EPR spectrum of 3. 
ll.0000 f 
!  I I I I 1 
0 301, 6”” 91,” IZD(I I SO” ,800 
TlME (SECON”S, 
Fig. 2. Plot of absorbance vs. time for the oxidation of catechol 
catalyzed by 2 (A), 3 (B), 1 (C) and 4 (D, insert). 
presence of 1, 2 and 3, the rate at which o-quinone 
is produced is clearly dependent on the type of imidazole 
ligand present in the complex. Calculated activities for 
these three complexes are given in Table 2. It was not 
possible to compare the activity for 4 since the o- 
quinone produced during the first 2-3 min of the 
catalyzed reaction appears to poison the catalyst (see 
insert in Fig. 2). 
A number of dinuclear and mononuclear copper(I1) 
complexes have been studied with regard to their cat- 
alytic hydroxylation of monophenols and oxidation of 
catechols to o-quinones [18-23, 311. In tyrosinase and 
in synthetic copper(I1) dinuclear models, it is believed 
that two proximate metal atoms are needed to bond 
to the two hydroxyl oxygen atoms of catechols in the 
oxidation to o-quinones [31]. For non-planar mono- 
nuclear copper(I1) complexes, it has been proposed 
that the two copper(I1) atoms must be located at a 
distance of less than 5 A for bonding to the catechol 
hydroxyl groups and the subsequent two-electron trans- 
fer to dioxygen [31a]. In addition, Thompson and Cal- 
abrese [32] isolated and characterized a series of mono- 
nuclear Cu(I1) di-tert-butyl-o-semiquinone complexes 
from reactions of the corresponding catechol or ben- 
zoquinone with dinuclear and mononuclear Cu(I1) or 
Cu(1) complexes, respectively. It was concluded that 
the single-step two-electron oxidation of catechol by 
Cu(I1) complexes is not observed and o-benzoquinone 
was obtained only after exposure of the Cu(II)-o- 
semiquinone to dioxygen or by the addition of small 
molecules such as pyridine. This study indicates that 
the formation of mononuclear Cu(II)-o-semiquinone 
complexes as an intermediate should be considered in 
the catecholase-mimetic activity of Cu(I1) complexes. 
In a recent study of the catecholase-mimetic activity 
of mononuclear five-coordinate copper(I1) complexes 
Malachowski ef al. [23] showed that the rate of oxidation 
of catechol to o-quinone is dependent on the ease of 
loss of the fifth ligand. This permits the formation of 
a Cu(I1) catecholate complex. For complexes reported 
in this paper the geometry is purported to be a severely 
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distorted octahedron that contains the CuN,02. * * 0, 
chromophore in which the fifth and the sixth donor 
atoms are the weakly coordinated second carboxylate 
oxygen atoms. The weakly interacting oxygen atoms are 
likely to dissociate to provide sites on Cu(I1) for catechol 
bonding. Dissociation of the weakly bonding donors 
would also facilitate any necessary ligand rearrangement 
induced by catechol bonding. The catecholase-mimetic 
activity of the benzimidazole adduct 1 is higher than 
that of the 2-methylbenzimidazole adduct 2 and me- 
tronidazole adduct 3 (Table 2). This may be due to 
steric hindrance caused by the proximity of the methyl 
group to the nitrogen donor atom in 2 and 3. The 
presence of methyl groups could render the approach 
of catechol to Cu(I1) sites more difficult in these two 
adducts when compared to the benzimidazole adduct. 
Conclusions 
Four new copper(I1) monomers have been prepared 
and characterized. Spectral data suggest that these 
complexes contain the CuO,N, chromophore. Oxidation 
of catechol to o-quinone by these four complexes has 
been studied. These copper complexes catalyze the 
oxidation of catechol, however, the rate of reaction is 
dependent on the nature of the N-containing ligand. 
Furthermore, the 2-methyl-5nitrobenzimidazole com- 
plex which initially is the most reactive complex quickly 
poisons the catalyst and the oxidation ceases. The exact 
manner in which the catalyst is poisoned is not known 
at this time but is under investigation. 
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